Table 4.
Summary of common ADR in 2% or more patients by with/without moisturizers at baseline (ITT population)
| CLNP/BPO 3% | ADA + CLNP | |||||
|---|---|---|---|---|---|---|
| With moisturizer (n = 82) | Without moisturizer (n = 90) | Total (n = 172) | With moisturizer (n = 90) | Without moisturizer (n = 87) | Total (n = 177) | |
| Any event | 13 (15.9) | 16 (17.8) | 29 (16.9) | 24 (26.7) | 41 (47.1) | 65 (36.7) |
| Application‐site dryness | 6 (7.3) | 10 (11.1) | 16 (9.3) | 12 (13.3) | 30 (34.5) | 42 (23.7) |
| Application‐site pain | 1 (1.2) | 2 (2.2) | 3 (1.7) | 8 (8.9) | 8 (9.2) | 16 (9.0) |
| Application‐site erythema | 3 (3.7) | 1 (1.1) | 4 (2.3) | 6 (6.7) | 5 (5.7) | 11 (6.2) |
| Application‐site pruritus | 4 (4.9) | 1 (1.1) | 5 (2.9) | 6 (6.7) | 2 (2.3) | 8 (4.5) |
| Application‐site exfoliation | 2 (2.4) | 1 (1.1) | 3 (1.7) | 3 (3.3) | 3 (3.4) | 6 (3.4) |
| Application‐site reaction | 0 | 2 (2.2) | 2 (1.2) | 2 (2.2) | 3 (3.4) | 5 (2.8) |
| Application‐site dermatitis | 0 | 0 | 0 | 2 (2.2) | 1 (1.1) | 3 (1.7) |
Application‐site reaction consists of “application site asteatosis”, “application site skin tightness” in verbatim text. ADA, adapalene; ADR, adverse drug reaction; BPO, benzoyl peroxide; CLNP, clindamycin phosphate; ITT, intent‐to‐treat. All values are n (%).